secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0000950170-23-011487
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics appoints Craig Collard as CEO, Adam Morgan as Chairman
-------------------------------------------------------------------------

- Craig Collard appointed CEO effective April 3, 2023, succeeding Barry Quart who stepped down.
- Adam Morgan elected Chairman of the Board; CEO and Chairman roles are now separate.
- Collard's compensation: $650,000 base salary, 75% target bonus, equity grants including 3M stock options and up to 4.25M performance-based options.
- Board reduced to seven members as part of governance changes.
- Departure of Barry Quart not due to any disagreement; he may assist with transition under a consulting agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/hrtx-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer